Curated News
By: NewsRamp Editorial Staff
April 21, 2025
Soligenix Advances CiVax Vaccine Amid Rising COVID-19 Deaths
TLDR
- Soligenix gains competitive advantage with CiVax vaccine for rapid and broad protection against COVID-19 variants.
- CiVax, a heat-stable COVID-19 subunit vaccine, demonstrates rapid and broad protection in recent preclinical studies.
- CiVax by Soligenix contributes to a safer future by fighting COVID-19 and providing effective protection against new variants.
- Recent data highlights the urgent need for effective COVID-19 protective measures while CiVax offers hope with its rapid protection.
Impact - Why it Matters
This news highlights the ongoing threat of COVID-19 despite global efforts. The development of CiVax offers hope for effective protection against the virus and its variants, emphasizing the critical need for continued research and innovation in the fight against the pandemic.
Summary
An increase in deaths from COVID-19 underscores the persistent danger of the virus, highlighting the urgent need for effective protective measures and treatments. Soligenix is tackling this challenge with the development of CiVax, its heat-stable COVID-19 subunit vaccine candidate, showing promising results in preclinical studies in providing broad protection against multiple variants.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Soligenix Advances CiVax Vaccine Amid Rising COVID-19 Deaths
